Translation of Anticancer Efficacy From Nonclinical Models to the Clinic by Stroh, M et al.
 
Translation of Anticancer Efficacy From Nonclinical Models to the
Clinic
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Stroh, M, D G Duda, C H Takimoto, S Yamazaki, and P Vicini.
2014. “Translation of Anticancer Efficacy From Nonclinical
Models to the Clinic.” CPT: Pharmacometrics & Systems
Pharmacology 3 (8): e128. doi:10.1038/psp.2014.28.
http://dx.doi.org/10.1038/psp.2014.28.
Published Version doi:10.1038/psp.2014.28
Accessed February 16, 2015 11:33:04 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12987402
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAACitation: CPT Pharmacometrics Syst. Pharmacol. (2014) 3, e128;  doi:10.1038/psp.2014.28
© 2014 ASCPT  All rights reserved 2163-8306/14
www.nature.com/psp
Successful submission and regulatory approval of innovative 
drugs is growing ever more challenging. Each drug candidate 
must navigate the so-called drug discovery and development 
“funnel,” characterized by a series of steps and associated 
probabilities of success. The relatively low historical success 
rate for registration of cancer drugs1 suggests that the funnel 
can be prohibitively narrow for this medication class. This can 
be attributed in part to discovery and development constraints 
that are either specific to, or more pronounced in, oncol-
ogy relative to other therapeutic areas. Difficulties in proper 
interpretation and quantitative translation of oncology animal 
cancer model data, commonly originating from mice, are fre-
quently cited as important factors that act to narrow the funnel.
Preclinical mouse cancer models have provided a wealth 
of information regarding our understanding of tumor biology. 
However, extrapolation from bench to bedside has been prob-
lematic, leading to a vigorous scientific debate regarding the 
predictability of antitumor efficacy from mouse experiments. 
Even with this uncertainty, mouse cancer models occupy a 
central role, especially in early drug development and the 
translational space. The need to increase drug development 
efficiency remains a major priority for grievous diseases such 
as cancer. Thus, the robust clinical translation of mouse data 
is of correspondingly high importance.
Our understanding of the factors that influence extrapola-
tion of mouse findings to the clinic is evolving and suggests 
a high degree of complexity. Though cancer is characterized 
by uncontrolled cell proliferation caused by oncogenic driver 
mutations, the tumor microenvironment—comprised of blood 
and lymphatic vessels, nonmalignant host cells, and extra-
cellular matrix—is critical to cancer progression and treat-
ment (Figure 1). Indeed, 10 drugs targeting the tumor 
vasculature are currently approved by the US Food and 
Drug Administration.2 Others targeting the immunosuppres-
sive or desmoplastic tumor microenvironment are in clinical 
development. Accordingly, our ability to reasonably approxi-
mate the human disease in mice should not be determined 
solely by selection of a relevant cancer cell line or model, but 
also by local interactions with the stroma and parenchyma, 
as well as systemic interactions with the host. Our current 
understanding of “cancer as an organ system” suggests that 
such interactions are influential, at both individual tumor 
compartment (i.e., tumor vessels, perivascular cells, extra-
cellular matrix, etc.) and molecular levels. For example, at 
the compartmental level, intravital imaging provided direct 
evidence that tumor vessel morphology is vastly different fol-
lowing transplantation of the same cancer cell line at multiple 
sites in mice.2 These morphological changes in vessel char-
acteristics bring important consequences for drug delivery 
to the tumor. Accordingly, extrapolation of preclinical tumor 
drug delivery findings to the clinic may be especially sensitive 
to this kind of cancer cell–stromal cell interaction. In addition, 
we see evidence of cancer cell–  stromal cell interactions at 
the molecular level. A first example comes from medulloblas-
toma, the most frequent pediatric brain malignancy. A recent 
study suggests that medulloblastoma growth depends upon 
PlGF secretion from the cerebellar stroma irrespective of 
its genetic subtype and that PlGF expression is mediated 
by tumor-derived Sonic hedgehog.3 As with the previous 
example at compartmental level, this molecular level cancer 
cell–stromal cell interaction finding has potentially important 
ramifications for clinical translation; selection of a relevant 
preclinical model was essential in revealing this tissue- 
specific interaction. Similarly, at molecular level, a growing 
body of evidence implicates activation of the chemokine 
CXCL12 (stromal cell-derived factor-1α) pathway in tumor 
resistance to various treatments.4 The resistance mecha-
nism involves direct promotion of cancer cell survival and 
invasion, as well as indirect effects on tumor recurrence and 
metastasis via the stroma. Accordingly, the clinical transla-
tion of anti-CXCL12 agents for use as sensitizers to existing 
cancer therapies should rely upon the development and use 
of preclinical models capable of capturing the response to 
these same therapies in patients.
Given the challenges in fully capturing the cancer dis-
ease process in the mouse model, a translational program 
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Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been 
challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human 
cancer pathophysiology and end with challenges in generating robust translatable preclinical end points. A comprehensive 
approach that considers clinically relevant mouse models with both an integrated biomarker strategy and a complementary 
modeling and simulation effort will strengthen the current oncology drug development paradigm.
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including quantitative assessment of continuous pharma-
codynamic biomarkers (complementary to the existing dis-
covery framework) promises to augment the cumulative 
database available for clinical translation and subsequent 
development. This is especially true given continuing increas-
ing trends in developing molecularly targeted (vs. cytotoxic) 
agents in cancer, where mechanistic biomarkers may pro-
vide important insight into the intended mechanism of action. 
Despite this promise, biomarker approaches to inform clinical 
development in oncology have thus far been limited. A review 
of 2,483 phase I trials submitted to the American Society of 
Clinical Oncology suggested that 20% of trials incorporated 
biomarker assessments.5 Use of these biomarker data in 
clinical decision-making (i.e., proof of mechanism) was rela-
tively infrequent, with biomarker-based support for phase II 
dose selection reported only in 13% of cases.
To increase the impact of biomarkers in oncology, it is 
important to have a robust framework for biomarker imple-
mentation into clinical development. The pharmacologi-
cal audit trail (PhAT) can be especially useful.6 The PhAT 
partitions the determinants of drug action into a series of 
multilevel connected questions, progressing from target mol-
ecule to clinical response. Measurements at each of these 
levels permit a more holistic understanding of the drug’s 
Figure 1  The tumor microenvironment. The tumor microenvironment is comprised of blood and lymphatic vessels, nonmalignant host 
cells, and extracellular matrix, all of which shape tumor progression and response or resistance to therapy. Courtesy of Lance L. Munn, 
Massachusetts General Hospital and Harvard Medical School, Boston, MA.
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Figure 2  Translational phase I study with biomarker-defined end points. Phase I oncology studies classically treat advanced cancer patients 
in cohorts of three at progressively increasing starting dose levels until drug-related toxicities are observed. When the incidence and severity 
of these toxicities exceed levels predefined as dose limiting in the study protocol, dose escalation is halted. Additional patients are then treated 
at a lower dose to determine the maximum tolerated dose level. In a modern translational phase I study design, these classical phase I end 
points are augmented by pharmacodynamic biomarker monitoring to define the minimum exposures associated with biological activity. At the 
end of dose escalation, patient expansion cohorts are often added to collect additional biomarker, safety, and pharmacokinetic data. Thus, 
these early clinical studies mimic the comprehensive preclinical studies used to define pharmacologically active drug exposures. Modeling 
and simulation can be used at every step along the sequence to integrate exposure, biomarker, and other data collected during the trials. BED, 
biologically effective dose; DLT, dose-limiting toxicity; MTD, maximum tolerated dose.
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performance and provide context both for interpretation of 
biomarker readout and for broader use in dose selection. The 
emphasis upon interconnectivity between drug and effect 
enables identification of a biologically effective dose; this is 
in contrast to the more common selection of maximally tol-
erated dose that in turn focuses only on one aspect of the 
PhAT (i.e., tolerability). Accordingly, the PhAT naturally lends 
itself to defense of biologically effective dose as an alterna-
tive to dose selection based upon maximally tolerated dose. 
Figure 2 provides an example of how we can incorporate this 
approach into early development clinical designs. Examples 
of studies using biologically effective dose as a primary end 
point include trials with agents such as PARP inhibitors and 
antiangiogenic agents.7,8
Modeling, encompassing the “fit for purpose” continuum 
from mechanistic systems pharmacology to pharmacomet-
rics through semi-mechanistic pharmacokinetics/pharma-
codynamics (PK-PD), provides a quantitative approach to 
invoke and implement PhAT principles in drug development 
and to address the significant challenge of scaling results 
to the clinic. Both mechanistic and semi-mechanistic mod-
els can be amenable to scaling. For example, systems 
approaches have been used to capture the pathophysio-
logical determinants of tumor drug delivery to the intended 
target and to successfully project the impact of elevated 
interstitial fluid pressure on fluid flow rates exiting the tumor, 
both in rodent models and in human cancers.2 The semi-
mechanistic tumor growth inhibition (TGI) model also lends 
itself to scaling. With the TGI model, the observed tumor 
size is usually expressed as a competition between tumor 
growth in the absence of drug (system property) and kill rate 
(drug property); the TGI model may be further modified to 
allow for resistance and decreased drug effect in time. This 
conceptual partition provides the framework to scale find-
ings from mice to the clinic, either directly or in conjunction 
with biomarker data, which can also be integrated in the 
modeling process.9
The case example of crizotinib (PF02341066; Xalkori), a 
dual inhibitor of anaplastic lymphoma kinase (ALK) and mes-
enchymal-epithelial transition factor (MET), illustrates the use 
of TGI modeling together with biomarker data to infer mini-
mally efficacious levels of biomarker modulation (i.e., ALK 
and MET inhibition).10 In this example, a modeling and simula-
tion approach was used to describe two exposure–response 
relationships, i.e., between crizotinib levels and the extent of 
inhibition of biomarker and tumor growth, respectively. This 
approach provides a quantitative framework to benchmark 
biomarker readout against TGI; the potency of crizotinib was 
captured as the minimal efficacious concentration for 50% 
of full effect (EC50) on TGI. Comparing the EC50 estimate for 
TGI and biomarker inhibition, the authors postulated a mini-
mal required biomarker inhibition in the clinic. To optimally 
inform both TGI and biomarker inhibition relationships, MET 
and ALK inhibition data were obtained in biologically appro-
priate settings: GTL16 gastric and H3122 non–small-cell lung 
carcinoma mouse models, respectively. The EC50 for TGI was 
found to be similar to the EC50 for ALK inhibition and the EC90 
for MET inhibition; accordingly, minimal required ALK and 
MET biomarker inhibition were predicted to be 50 and 90%, 
respectively. Subsequently, the crizotinib PK-PD relationship 
was simulated using the predicted (pre-first-in-human) and 
observed (post-first-in-human) pharmacokinetic parameters 
in patients. In these simulations, the crizotinib pharmacody-
namics and unbound concentration (relationships the latter 
consistently with the “free drug hypothesis”) from nonclinical 
models were assumed to be analogous to those in cancer 
patients. The PK-PD prediction at the recommended phase 
II dose was especially important for decision making. That is, 
at 250 mg twice daily crizotinib, the model-predicted inhibition 
for both ALK and MET were higher (specifically, greater than 
75% for ALK and 95% for MET) than their minimal required 
inhibition proposed from biomarker and TGI modeling, sug-
gesting that target modulation in patients at the approved 
dosing regimen would be sufficient to attain desired antitu-
mor efficacy.
In summary, incomplete understanding of translation early 
in oncology drug development undermines the foundation 
for subsequent steps in the drug development process. The 
mouse model lies at the center of the translational effort in 
oncology, but it is frequently criticized as being poorly infor-
mative. Quantitative approaches have had significant impact 
in oncology drug development; their application to the inter-
pretation of mechanistic nonclinical discovery data promises 
to continue providing significant value in the future. There is 
not a single factor limiting the value of the mouse model in 
informing early oncology development; thus, approaches to 
increase its value have to be multifaceted. Experiments in 
clinically relevant settings, coupled with an integrated mecha-
nistically based biomarker program, provide the missing tiles 
in the current development paradigm mosaic. In addition, 
an equally active modeling and simulation effort can act to 
assemble these data pieces into a stronger foundation for 
bringing promising cancer candidates to the clinic more rap-
idly and efficiently.
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